Company intelligence / Profile preview

Shanghai Xinyi Wanxiang Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

The company holds over 180 product approvals, with a strong commercial presence in China and international markets (notably South Africa, Southeast Asia). Products and clinical programs span cardiovascular, anti-infective, metabolic, digestive, nervous system, and dermatology, with focus on solid and soft capsule formulations. Four drug approvals are noted, indicating mature manufacturing and market presence.

Therapeutic areas: EndocrinologyGastroenterologyCardiovascularOncologyNeurology
Modalities: Small moleculeBiologic
Industry: Pharma

Partnerships

Distribution and approvals in South Africa and Southeast AsiaPotential ties to CanSino for vaccine manufacturing via parent group

Beyond the preview

Go deeper on Shanghai Xinyi Wanxiang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Xinyi Wanxiang Pharmaceutical.

Explore the full profile